<DOC>
	<DOCNO>NCT02527265</DOCNO>
	<brief_summary>Primary Objective : -To ass safety tolerability Afrezza child age 4 17 year type 1 diabetes mellitus ( T1DM ) . Secondary Objectives : - To assess ability titrate prandial supplemental dos Afrezza meal . - To assess pharmacokinetics ( PK ) follow prandial dose Afrezza child age 4 17 year T1DM .</brief_summary>
	<brief_title>Afrezza Safety Pharmacokinetics Study Pediatric Patients</brief_title>
	<detailed_description>The patient expect participate study approximately 6 8 week Screening final follow-up visit . Patients complete 4 week Afrezza treatment show safe well control Afrezza + basal insulin option continue extension treatment 1 year .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Inclusion criterion : Children adolescent ≥4 ≤17 year . Clinical diagnosis T1DM use insulin least 1 year . On regimen stable total daily dose ( ±10 % ) basal insulin administer daily evening . Currently receive stable regimen basal/bolus insulin administer multiple daily injection ( MDI ) least 6 week prior inclusion . Patient stable regimen insulin via continuous subcutaneous insulin infusion ( CSII ) may enrol satisfy enrollment criterion willing convert MDI duration trial ; must maintain stable MDI dose 6 week prior inclusion prebreakfast selfmonitored plasma glucose ( SMPG ) value 80 250 mg/dL ( 4.4 13.9 mmol/L ) 5 7 reading previous week inclusion . Total daily insulin dose ≤1.5 IU/kg/day minimum 3 IU rapidacting insulin analog ( RAA ) every meal maximum 12 IU RAA breakfast . Glycated hemoglobin ( HbA1c ) 7.0 % 10.0 % time screen . Prebreakfast SMPG value 80 250 mg/dL ( 4.4 13.9 mmol/L ) 5 7 reading previous week . Fasting serum Cpeptide ≤0.3 ng/mL . Exclusion criterion : Body mass index ( BMI ) 25th 95th percentile age gender accord Centers Disease Control Prevention ( CDC ) growth chart . History physician diagnosis asthma clinically important pulmonary disease , use medication treat condition within last year . Forced expiratory volume 1 second ( FEV1 ) &lt; 70 % Third National Health Nutrition Examination Survey ( NHANES III ) predict child ≥8 year age Wang predict child &lt; 8 year age . Forced vital capacity ( FVC ) &lt; 70 % NHANES III predict child ≥8 year age Wang predict child &lt; 8 year age . Allergy known hypersensitivity Afrezza drug similar chemical structure . Unstable diabetes control , define 2 episode severe hypoglycemia ( episode associate seizure , coma , loss consciousness ) hospitalization emergency room visit poor diabetes control , ketoacidosis , hypoglycemia , hyperglycemia within precede 3 month screen . Serum creatinine ≥ upper limit normal age . Respiratory tract infection within 30 day screen screen initiation treatment period . ( Patient may return 4 week resolution infection rescreening . ) Evidence complication diabetes ( proliferative retinopathy , autonomic neuropathy , nephropathy , etc ) , probable need laser photocoagulation , vitrectomy , specific treatment diabetic retinopathy come year . Smoking tobacco substance positive urine cotinine testing ( &gt; 100 ng/mL ) . Positive urine drug screen . Positive urine pregnancy test female patient childbearing potential . Inability perform study procedure include pulmonary function test . Exposure investigational product ( ) past 3 month . History eat disorder . Any disease exposure medication , , judgment principal Investigator , may impact glucose metabolism . Any concurrent medical major psychiatric condition make patient unsuitable clinical study impair patient 's ability participate study . Patients refuse follow continuous glucose monitoring ( CGM ) guideline . Patients take acetaminophen contain medication regular basis anticipate take study period unable and/or unwilling substitute nonacetaminophen contain medication . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>